View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 14, 2021updated 11 Jul 2022 2:48pm

Jemincare concludes Phase I trial of anti-SARS-CoV-2 antibody

None of the subjects in the trial experienced serious adverse events related to the antibody treatment.

Jemincare group has announced the completion of the Phase I clinical trial of its self-developed anti-SARS-CoV-2 neutralising antibody, JMB2002.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The single centre, randomised, double-blind, placebo-controlled, single-dose escalation trial assessed tolerability, safety, pharmacokinetic characteristics and immunogenicity of JMB2002 in healthy subjects.

The company commenced the trial in January. It enrolled 40 participants in four groups to receive low to high doses of the antibody.

All 40 subjects completed the trial, Jemincare noted.

According to the results from the trial, grade 2 adverse events (TEAE) associated with the study drug were reported in one subject.

The other TEAEs were observed to be grade 1 and all TEAEs were in remission or fully recovered.

No trial subjects experienced any serious adverse events (SAE) related to the antibody.

With regard to pharmacokinetics, after a single intravenous infusion of JMB2002, the maximum concentration (Cmax) and area under the curve (AUC) raised on increasing dosage while the time to reach Cmax (Tmax) reduced with the rise in dosage.

No substantial differences in the parameters such as T1/2, Vz, CLz, λz and MRT were reported among various dose groups.

In terms of immunogenicity, an anti-drug antibody was observed in one subject before and after the treatment while no anti-drug antibodies were seen in other trial subjects.

The trial findings show that JMB2002 can be progressed to additional assessment in clinical efficacy study in Covid-19 patients, in a bid to offer the antibody as Covid-19 treatment.

Currently, Jemincare is developing novel broad-spectrum neutralising antibodies to deal with the viral escape challenge.

So far, the research and development (R&D) team has developed second-generation neutralising antibodies with increased neutralising activity against all variants of concern such as the Alpha, Beta, Gamma and Delta variants in the pseudo-virus neutralising assay.

In addition, these antibodies could be offered as a cocktail treatment that offers additional options to manage the Covid-19 pandemic situation and to prevent the immune-escape of SARS-CoV-2.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena